Correction for: Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy (Molecular Pharmaceutics (2015) 12 (2574-2581) DOI: 10.1021/acs.molpharmaceut.5b00118);Spray Dried Aerosol Particles of Salts for Tuberculosis Therapy

Molecular Pharmaceutics

Volumn 12, Issue 8, 2015, Pages 2574-2581

  Durham, P G ^a   Zhang, Y ^a   German, N ^a,d   Mortensen, N ^a   Dhillon, J ^b   Mitchison, D A ^b   Fourie, P B ^c   Hickey, A J ^a  

^a RTI INTERNATIONAL   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

antimycobacterial activity; pulmonary drug delivery; pyrazinoic acid salts; spray drying; therapeutic aerosols; tuberculosis

Indexed keywords

AMMONIUM DERIVATIVE; LEUCINE; PYRAZINAMIDE; PYRAZINOIC ACID; TUBERCULOSTATIC AGENT; INORGANIC SALT; NANOPARTICLE; NOSE SPRAY;

AEROSOL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG POTENCY; IN VITRO STUDY; MELTING POINT; MOISTURE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PH; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; SPRAY DRYING; THERMOGRAVIMETRY; TUBERCULOSIS; WATER CONTENT; X RAY POWDER DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; DESICCATION; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; POWDER DIFFRACTION; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; DESICCATION; DRY POWDER INHALERS; HUMANS; NANOPARTICLES; NASAL SPRAYS; PARTICLE SIZE; POWDER DIFFRACTION; PYRAZINAMIDE; SALTS; TUBERCULOSIS; X-RAY DIFFRACTION;

EID: 84938389586     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00673     Document Type: Erratum

References (36)

1. World Heath Organization, Fact Sheet No. 104, 2015.
2. Fox, W. Whither short-course chemotherapy? Br. J. Dis. Chest 1981, 75 (4) 331-57
3. Essentially of Pyrazinamide Workshop. In Stop TB Partnership Working Group on New Drugs; 2011, Bethesda, MD.
4. Mitchison, D. A. Role of individual drugs in the chemotherapy of tuberculosis Int. J. Tuberc. Lung Dis, 2000, 4 (9) 796-806
5. Lu, P. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels Antimicrob. Agents Chemother. 2011, 55 (11) 5354-7
6. Cole, S. T. Microbiology. Pyrazinamide - old TB drug finds new target Science 2011, 333 (6049) 1583-4
7. Shi, W. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 2011, 333 (6049) 1630-2
8. Kjellsson, M. C. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions Antimicrob. Agents Chemother. 2012, 56 (1) 446-57
9. Matthews, J. IX. Pyrazinamide and isoniazid used in the treatment of pulmonary tuberculosis Am. Rev. Respir. Dis. 1960, 81, 348-351
10. McKenzie, D. The effect of nicotinic acid amide on experimental tuberculosis of white mice J. Lab. Clin. Med. 1948, 33, 1249-1253
11. Solotorovsky, M. Pyrazinoic acid amide; an agent active against experimental murine tuberculosis Proc. Soc. Exp. Biol. Med. 1952, 79 (4) 563-565
12. Yeager, R. L.; Munroe, W. G.; Dessau, F. I. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis Am. Rev. Tuberc. 1952, 65 (5) 523-46
13. McCune, R.; Tompsett, R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy J. Exp. Med. 1956, 104, 737-762
14. East African/British Medical Research Councils. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis Lancet 1972, 299 (7760) 1079-1085
15. Konno, K.; Feldmann, F. M.; McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli Am. Rev. Respir. Dis. 1967, 95 (3) 461-9
16. Zhang, Y.; Mitchison, D. The curious characteristics of pyrazinamide: a review Int. J. Tuberc. Lung Dis. 2003, 7 (1) 6-21
17. Scorpio, A. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1997, 41 (3) 540-3
18. Scheuch, G. Clinical perspectives on pulmonary systemic and macromolecular delivery Adv. Drug Delivery Rev. 2006, 56, 996-1008
19. Smola, M.; Vandamme, T.; Sokolowski, A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases Int. J. Nanomed. 2008, 3, 1-19
20. Garcia-Contreras, L. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob. Agents Chemother. 2007, 51, 2830-2836
21. Fiegel, J. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm. Res. 2008, 25 (4) 805-11
22. Tsapis, N. Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis 2003, 83, 379-385
23. Muttil, P.; Wang, C.; Hickey, A. J. Inhaled drug delivery for tuberculosis therapy Pharm. Res. 2009, 26 (11) 2401-16
24. Misra, A. Inhaled drug therapy for treatment of tuberculosis Tuberculosis (Edinburgh) 2011, 91 (1) 71-81
25. Convention, U.S.P., U.S. Pharmacopeia National Formulary (2011): USP 34 NF 292011: United States Pharmacopeial.
26. Srichana, T.; Martin, G. P.; Marriott, C. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro Eur. J. Pharm. Sci. 1998, 7 (1) 73-80
27. International Standards Organization. Anaesthetic and respiratory equipment. In Nebulizing systems and components; 2009.
28. Chuck, R. J.; Zacher, U. Spray drying an aqueous solution of ammonium nicotinate; heating aftertreatment, 2002, Google Patents.
29. Vehring, R. Pharmaceutical Particle Engineering via Spray Drying Pharm. Res. 2008, 25 (5) 999-1022
30. JCPDS - International Centre for Diffraction Data American Society for Testing Materials, Powder Diffraction File: Inorganic and organic 2001,: JCPDS International Centre for Diffraction Data.
31. Prasad, K. D. Differential Cocrystallization Behavior of Isomeric Pyridine Carboxamides toward Antitubercular Drug Pyrazinoic Acid Cryst. Growth Des. 2015, 15 (2) 858-866
32. Lewis, M. W. Preparation of pyrazinoic acid, 1954, Google Patents.
33. McDermott, W.; Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro Am. Rev. Tuberc. 1954, 70 (4) 748-54
34. von Ardenne, M.; Kruger, W. Local tissue hyperacidification and lysosomes Front. Biol. 1979, 48, 161-94
35. Jindani, A.; Dore, C. J.; Mitchison, D. A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days Am. J. Respir. Crit. Care Med. 2003, 167 (10) 1348-54
36. Ellard, G. A. Absorption, metabolism and excretion of pyrazinamide in man Tubercle 1969, 50 (2) 144-158